FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, chemical-pharmaceutical industry and concerns agents possessing the nootropic and neuromodulatory activity. A tabletted pharmaceutical composition possessingthe nootropic and neuromodulatory activity, characterised by the fact that as an active substance, it contains N-cabamoylmethyl-4-phenyl-2-pyrrolidone; the additives are lactose monohydrate, microcrystalline cellulose, sodium croscarmellose, colloidal silicon dioxide (aerosil) and calcium stearate. The tablets of the composition are prepared by direct compression.
EFFECT: produced preparation has a lower variability of the pharmacological action.
3 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION IN FORM OF TABLET AND METHOD OF OBTAINING THEREOF | 2014 |
|
RU2546002C1 |
| PHARMACEUTICAL COMPOSITIONS BASED ON N-CARBAMOYL-METHYL-4-PHENYL-2-PYRROLIDONE | 2012 |
|
RU2560691C2 |
| N-CARBAMOYLMETHYL-4-PHENYL-2-PYRROLIDONE NEW COMPOSITION | 2017 |
|
RU2696277C2 |
| NOVEL COMPOSITIONS OF N-CARBAMOYLMETHYL-4-PHENYL-2-PYRROLIDONE | 2018 |
|
RU2699669C1 |
| PHARMACEUTICAL COMPOSITION IN FORM OF SOLUTION FOR INJECTION AND METHOD FOR PRODUCTION THEREOF | 2013 |
|
RU2524651C1 |
| COMBINED REMEDY FOR IMPROVING THE FUNCTIONAL STATE OF THE BRAIN | 2021 |
|
RU2782672C1 |
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| PHARMACEUTICAL COMPOSITION ELICITING NOOTROPIC ACTIVITY AND METHOD FOR ITS PREPARING | 2003 |
|
RU2240783C1 |
| PHARMACEUTICAL COMPOSITION OF OXY-ETHYLAMMONIUM METHYLPHENOXYACETATE | 2020 |
|
RU2762552C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRINE, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDINE | 2016 |
|
RU2736941C2 |
